Wall Street Zen Upgrades Grace Therapeutics (NASDAQ:GRCE) to Hold

Grace Therapeutics (NASDAQ:GRCE) was upgraded by Wall Street Zen to a “hold” rating in a research report issued on Friday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Grace Therapeutics has an average rating of “Hold” and an average price target of $12.00.

Grace Therapeutics Stock Performance

GRCE traded up $0.02 during trading on Friday, reaching $3.82. 92,590 shares of the company’s stock were exchanged, compared to its average volume of 119,145. The company’s fifty day moving average price is $3.41 and its 200-day moving average price is $3.22. The firm has a market capitalization of $59.10 million, a PE ratio of -6.16 and a beta of 0.55. Grace Therapeutics has a fifty-two week low of $1.75 and a fifty-two week high of $3.99.

Grace Therapeutics (NASDAQ:GRCE) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). Research analysts forecast that Grace Therapeutics will post -1.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of GRCE. Stratos Wealth Partners LTD. bought a new position in shares of Grace Therapeutics during the fourth quarter worth approximately $39,000. SeaCrest Wealth Management LLC acquired a new stake in Grace Therapeutics during the third quarter worth approximately $42,000. Millington Financial Advisors LLC acquired a new position in Grace Therapeutics in the 2nd quarter valued at $59,000. Palumbo Wealth Management LLC acquired a new position in Grace Therapeutics in the 2nd quarter valued at $144,000. Finally, ADAR1 Capital Management LLC increased its position in shares of Grace Therapeutics by 98.4% in the third quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock worth $1,043,000 after purchasing an additional 173,823 shares during the period. 6.08% of the stock is owned by institutional investors and hedge funds.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.